Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
Conditions:   Non Small Cell Lung Cancer Metastatic;   Leptomeningeal Metastasis;   Brain Metastases;   EGFR Activating Mutation Intervention:   Drug: Osimertinib Sponsor:   Intergroupe Francophone de Cancerologie Thoracique Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 18, 2020 Category: Research Source Type: clinical trials